Vaneck UCITS ETFs PLC - Vaneck Genomics And Healthcare Innovators UCITS ETF (LON:CURE)

Assets	15.88M
Expense Ratio	0.35%
PE Ratio	28.49
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+30.53%

Volume	168
Open	28.16
Previous Close	27.04
Day's Range	28.16 - 28.16
52-Week Low	19.21
52-Week High	28.16
Beta	n/a
Holdings	56
Inception Date	Sep 2, 2022

About CURE

CURE.L was created on 2022-09-02 by VanEck. The fund's investment portfolio concentrates primarily on theme equity. The Funds investment objective is to replicate the price and the performance, before fees and expenses, of an index that provides exposure to the performance of a representative portfolio of companies involved in the genomic healthcare and electronic healthcare industries

• Asset Class: Equity
• Category: Theme
• Stock Exchange: London Stock Exchange
• Ticker Symbol: CURE
• Provider: VanEck
• Index Tracked: MVIS Global Future Healthcare ESG Index - Benchmark TR Net

Performance

CURE had a total return of 30.53% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.50%.

Top 10 Holdings

64.73% of assets

Name	Symbol	Weight
Moderna, Inc.	MRNA	11.29%
Natera, Inc.	NTRA	8.30%
Regeneron Pharmaceuticals, Inc.	REGN	7.81%
Veeva Systems Inc.	VEEV	7.14%
Vertex Pharmaceuticals Incorporated	VRTX	6.99%
DexCom, Inc.	DXCM	6.26%
Illumina, Inc.	ILMN	5.52%
Guardant Health, Inc.	GH	4.63%
BioNTech SE	BNTX	3.40%
Alnylam Pharmaceuticals, Inc.	ALNY	3.39%

Data Sources: S&P Global Market Intelligence, Twelve Data, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error